The therapeutic armamentarium for management of inflammatory bowel diseases has
expanded dramatically in the last 5 years, with the introduction of several medications with …

Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course
and a multifactorial pathogenesis. In contrast to the traditional concept of AD as solely a type …

Background The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral
JAK3/TEC family kinase inhibitor, is efficacious at doses of≥ 30 mg in patients aged≥ 12 …

Targeted systemic immune-modulating drugs to treat atopic dermatitis were highly
efficacious in randomized trials. Trials with limited number of subjects leave questions about …

Introduction Alopecia areata (AA) is an immune-mediated disease that causes non-scarring
hair loss. While acute, solitary patches often spontaneously remit, developing secondary …

Janus kinase inhibitors (JAKi) have revolutionized the treatment landscape for various
inflammatory and autoimmune diseases since their introduction in 2012. The expanded …

Janus kinase inhibitors (JAKi) are drugs that block tyrosine kinases responsible for
transducing cytokine signals. The first JAKi was approved by the US Food and Drug …

Aim This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in
the treatment of generalized eosinophilic pustular folliculitis (EPF). Methods We present a …

Drug-induced acne is a common side effect to a wide array of pharmacological therapies
and is characterized by a monomorphic, papulopustular eruption typically affecting the face …

Acneiform eruptions have been observed and reported in clinical trials for tyrosine kinase 2
(TYK2) inhibitors. However, data on their occurrence in real‐world settings remain limited …